A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2001
11/22/2001	WO2001087263A2 Delivery systems for treatment of vascular disease
11/22/2001	WO2001087262A2 Stabilized steroidal suspension
11/22/2001	WO2001087259A1 Anti-pollution composition based on anthocyanic pigments
11/22/2001	WO2001087255A1 External application for enhancing the skin permeability of the active components therein
11/22/2001	WO2001087254A1 Use of ellagic acid as anti-pollution cosmetic agent
11/22/2001	WO2001087253A1 Use of n,n'-dibenzyl ethylene diamine n,n'-diacetic acid derivatives as anti-pollution agent
11/22/2001	WO2001087236A2 Topical administration of pharmacological compositions for non-systemic treatment of pruritus
11/22/2001	WO2001087234A2 Treatment of autoimmune, proliferative and inflammatory diseases with compositions of non-ionic copolymers
11/22/2001	WO2001087232A2 Allantoin-containing skin cream
11/22/2001	WO2001087230A2 Chenodeoxycholic acid: anti-altered metabolism of vitamin b coenzymes, anti-mitotic, and anti-inflammatory, agent
11/22/2001	WO2001087229A2 Treating infections
11/22/2001	WO2001087228A2 Sustained release pharmaceutical composition containing glipizide and method for producing same
11/22/2001	WO2001087039A2 Treatment of neoplasia / transformation using pituitary tumor transforming gene 2
11/22/2001	WO2001087038A2 β-CARBOLINE DERIVATIVES USEFUL AS INHIBITORS OF PHOSPHODIESTERASE
11/22/2001	WO2001060312A8 Device for calculating elixir doses appropriate for a patient's weight
11/22/2001	WO2001046128A3 Tryptase inhibitors
11/22/2001	WO2001042246A3 PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
11/22/2001	WO2001041770A3 Nanoparticulate eplerenone compositions
11/22/2001	WO2001041535A3 Eplerenone crystalline form
11/22/2001	WO2001036977A3 Identification of disease markers involving mass-based-separation
11/22/2001	WO2001036476A3 Ing2, an iaps associated cell cycle protein, compositions and methods of use
11/22/2001	WO2001035947A3 Treating wasting syndromes with aryloxy propanolamines
11/22/2001	WO2001034128A3 Admixture for intravenous administration of linezolid and other antibacterial agents
11/22/2001	WO2001034126A3 Mesoprogestins (progesterone receptor modulators) as a component of compositions for hormone replacement therapy (hrt)
11/22/2001	WO2001034119A3 Inhibitors of crystallization in a solid dispersion
11/22/2001	WO2001034116A3 Pharmaceutical formulations comprising labdanes for the treatment of tumors or leukemias
11/22/2001	WO2001034093A3 Potentiation of prodrug efficacy
11/22/2001	WO2001032891A3 Human lipase
11/22/2001	WO2001030781A3 INHIBITORS OF αLβ2 MEDIATED CELL ADHESION
11/22/2001	WO2001030752A3 Indole compounds for treating bacterial infections
11/22/2001	WO2001030324A3 Use of acetylsalicylic acid and a preparation for treatment of prostatic hyperplasia
11/22/2001	WO2001027268A3 Cell-permeable peptide inhibitors of the jnk signal transduction pathway
11/22/2001	WO2001025239A3 Oxazinoquinolones useful for the treatment of viral infections
11/22/2001	WO2001025227A3 Quinolyl propyl piperidine derivatives and their use as antibacterial agents
11/22/2001	WO2001017211A3 Communications system
11/22/2001	WO2001015679A3 Mesoprogestins for the treatment and prevention of benign hormone dependent gynecological disorders
11/22/2001	WO2001012607B1 Pharmaceutical compositions comprising 4-quinolones for treating cancers
11/22/2001	WO2001009118A3 Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
11/22/2001	WO2001007637B1 Conditionally controlled, attenuated hiv vaccine
11/22/2001	WO2001005769A3 Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation
11/22/2001	WO2001000242A3 Polycation-based bioconjugates
11/22/2001	WO2000066165A8 Contraceptive compositions containing quinazolinone and benzoxazine derivatives
11/22/2001	WO2000059542A9 Method for a programmed controlled ovarian stimulation protocol
11/22/2001	WO2000056681A9 Thiourea and urea liquid-phase combinatorial libraries: synthesis and apoptosis induction
11/22/2001	WO2000055633A9 Methods of screening for colorectal cancer modulators
11/22/2001	WO2000010600A9 Activation and protection of t-cells (cd4+ and cd8+) using an h¿2? receptor agonist and other t-cell activating agents
11/22/2001	US20010044616 Surgical irrigation solution and method for inhibition of pain and inflammation
11/22/2001	US20010044584 In vivo delivery methods and compositions
11/22/2001	US20010044547 From l-mannonic-gamma-lactone intermediates; for prophylaxis of HIV/AIDS HIV
11/22/2001	US20010044544 Useful as high energy oxidizing agents in explosive and propellant formulations, and drugs for vasodilation
11/22/2001	US20010044538 Mitogen-activated protein (MAP) kinase; treating inflammatory diseases; compounds such as 3-(4-fluorophenyl)-1-hydroxy-2-(pyridin-4-yl)-1H-pyrrolo(3,2-b)pyridine
11/22/2001	US20010044537 Inhibit human factor Xa; treating thrombotic activity; 3-((3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-((2-(1,2 -dihydoxyethyl)-4-hydroxy-5-ethoxytetrahydrofuran-3-yl)oxy)-pyridin-2 -yl)oxy)4-hydroxybenzamidine
11/22/2001	US20010044536 Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants
11/22/2001	US20010044535 Heterocyclic compounds containing a guanidine mimic, for inhibition of cell adhesion, treatment of angiogenesis disorders, inflammation, cancer metastasis, diabetic retinopathy, thrombosis, restenosis, macular degeneration
11/22/2001	US20010044533 Purification process
11/22/2001	US20010044519 Bile sequestering polymer comprises a crosslinked, alkylated, cationic polyamine or polyallylamine homo- or co-polymer
11/22/2001	US20010044474 Hydrogel-driven layered drug dosage form
11/22/2001	US20010044473 Treating Parkinson's disease, attention deficit hyperactivity disorder, dementia, depression, schizophrenia and dysautonomia; monoamine oxidase B inhibitor
11/22/2001	US20010044472 Fluidizing agent, a binder compound, a starch, a disintegrant and a lubricant; free-flowing; tablets
11/22/2001	US20010044471 Hydrogenation of racemic 6-alkoxy-1H-indene-1,2(3H)-dione-2-oxime, with chiral acid, resolution, alkylation, bromination, carboxamidation
11/22/2001	US20010044469 Hypotensive agents
11/22/2001	US20010044468 Reduced in the body to produce a benzamidine; nontoxic
11/22/2001	US20010044467 A prostaglandin applied topically to the clitoris
11/22/2001	US20010044466 Anticancer and antitumor agents
11/22/2001	US20010044465 Use of L-carnitine and its alkanoyl derivatives in the preparation of medicaments with anticancer activity
11/22/2001	US20010044463 Methods for controlling gram negative bacteria in mammals
11/22/2001	US20010044462 Desmethyl tocopherols for protecting cardiovascular tissue
11/22/2001	US20010044460 Ophthalmic compositions for treating ocular hypertension
11/22/2001	US20010044459 Hydroxamic acid derivatives
11/22/2001	US20010044458 Treating diabetic nephropathy, glomerulonephritis, glomerular sclerosis, nephrotic syndrome, hypertensive nephrosclerosis, end stage renal disease and micoralbuminuria; thiazolidinediones
11/22/2001	US20010044456 Non-systemic control of parasites
11/22/2001	US20010044455 Method of treatment for decreasing mortality resulting from congestive heat failure
11/22/2001	US20010044453 Combination drug therapy for glycolipid storage diseases
11/22/2001	US20010044452 Anticonvulsants
11/22/2001	US20010044451 Tyrosine kinase inhibitors
11/22/2001	US20010044450 5-HT3 receptor antagonists such as alosetron to treat nonconstipated female irritable bowel syndrome
11/22/2001	US20010044449 Remedies for drug addiction
11/22/2001	US20010044448 Prevention/treatment of motor neuron diseases; amyotrophic lateral sclerosis
11/22/2001	US20010044447 Administering riluzole and pharmaceutically acceptable salts thereof and ergoline compound selected from nicergoline and lumilysergol
11/22/2001	US20010044446 Modulation of in vivo glutamine and glycine levels in the treatment of autism
11/22/2001	US20010044444 Pyrimidine 3-oxide compounds for inducing/stimulating hair growth and/or retarding hair loss
11/22/2001	US20010044442 Dimethoxy quinazolines for treating diabetes
11/22/2001	US20010044441 And female sexual dysfunction, premature labour or dysmenorrhea
11/22/2001	US20010044439 Method for using 2-aryloxyalkylaminobenzoxazoles and 2-aryloxyalkylaminobenzothiazoles as H3 antagonists
11/22/2001	US20010044438 Combination of specific alpha-adrenoceptor antagonists and muscarinic antagonists is administered simultaneously, separately or sequentially to treat the lower urinary tract symptoms associated with benign prostate hyperplasia
11/22/2001	US20010044437 Administration of substituted indolealkanoic acids to patients; treatment of gout and related diseases
11/22/2001	US20010044436 Bicyclic inhibitors of glycogen synthase kinase 3
11/22/2001	US20010044434 Treating timidity and enhancing libido in postmenopausal women, or treating male sexual dysfunction by administering to a patient in need thereof an effective amount of an estrogen agonist/antagonist
11/22/2001	US20010044432 Administering estradiol derivative
11/22/2001	US20010044431 Administering compounds in an amount capable of regulating TGF-beta expression in the ovarian epithelium and/or capable of altering expression of other surrogate biomarkers identified by microarray technology
11/22/2001	US20010044430 Cosmetic composition containing a steroid and a 2-alkylalkanol or an ester thereof
11/22/2001	US20010044429 Administering for 21 successive days to a female of childbearing age a combination of an estrogen and a progestogen in a contraceptively effective daily dosage
11/22/2001	US20010044428 Aminopyridines and methods of using thereof
11/22/2001	US20010044426 Cyclobutaindolecarboxamide compounds
11/22/2001	US20010044425 Therapeutically effective amount of ferrous ion and a therapeutically effective amount of an ascorbate
11/22/2001	US20010044424 Peritoneal dialysis solution containing modified icodextrins
11/22/2001	US20010044423 Promoting vesical mucosa epithelium dilatation and/or healing vesical mucosa of a patient's bladder by administering to inside of bladder a solution of hyaluronic acid and/or a salt thereof
11/22/2001	US20010044422 Administering oral mixture comprising Eclipta prostrata L., Angelica dahurica, Polygonum multiforum Thumb, Astragalus complanatus, Tribulus terrestris L. and other herbs or topical mixture of sulfur and kerosene
11/22/2001	US20010044421 Antimutagenic compositions for treatment and prevention of photodamage to skin
11/22/2001	US20010044420 Treatment of mammalian cancer

1 ... 5961 5962 5963 5964 5965 5966 5967 5968 5969 5970 5971 5972 5973 5974 5975 5976 5977 5978 5979 5980 5981 ... 7860